Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | CDK6 | Q00534 | 6/20 | 0.38 |
| ▸ | PIM1 | P11309 | 4/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CCND1 | P24385 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CDK7 | P50613 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | CCNH | P51946 | 1/20 | 0.37 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.35 |
| ▸ | HTR3B | O95264 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22075362 | 0.96 | CHRNB2 (0.44) | HTR6CDK6PIM1CHRNB2CHRNA4 | |
| SCHEMBL30579173 | 0.88 | CDK6 (0.47) | CDK6PIM1CCNT1CDK4CCNA2 | |
| SCHEMBL22075195 | 0.88 | CDK6 (0.47) | CDK6PIM1CCNT1CDK4CCNA2 | |
| SCHEMBL22075325 | 0.86 | CNR1 (0.37) | CDK6PIM1CCNT1CDK4CCNA2 | |
| SCHEMBL30579178 | 0.86 | CNR2 (0.37) | HTR6CNR1CNR2KCNH2 | |
| SCHEMBL30579275 | 0.86 | CNR1 (0.37) | CDK6PIM1CCNT1CDK4CCNA2 | |
| SCHEMBL22074878 | 0.86 | CNR2 (0.37) | HTR6CNR1CNR2KCNH2 | |
| SCHEMBL22074805 | 0.86 | HTR6 (0.44) | HTR6CDK6PIM1CHRNB2CHRNA4 | |
| SCHEMBL22075020 | 0.84 | MPL (0.35) | HTR6HDAC3CNR1CNR2KCNH2 | |
| SCHEMBL22074912 | 0.84 | MPL (0.35) | HTR6HDAC3CNR1CNR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | claimed |
| US-20210154178-A1 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | claimed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210154178-A1 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
| US-20210154178-A1 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
| US-10952996-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-23 | — | — | US | disclosed |
| US-10952996-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200188370-A1 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-06-18 | — | — | US | disclosed |
| US-20200188370-A1 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10952996-B2 | ALK5 inhibitors | ALK, ACVR1, ACVRL1 | HTR6 2117/4885CDK6 959/4885PIM1 357/4885 |
| US-20210154178-A1 | ALK5 INHIBITORS | ALK, ACVR1, ACVRL1 | HTR6 2117/4885CDK6 959/4885PIM1 357/4885 |
| US-11730720-B2 | ALK5 inhibitors | ALK, ACVR1, ACVRL1 | HTR6 2117/4885CDK6 959/4885PIM1 357/4885 |
| US-20200188370-A1 | ALK5 INHIBITORS | ALK, ACVR1, ACVRL1 | HTR6 2117/4885CDK6 959/4885PIM1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.